## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	CROSSMAN, et al.	)	_
SERIAL NO.:	10/527,271	) EXAMINER: JAVANMAR SAHAR	D,
FILED:	MARCH 8, 2005	ART UNIT: 1627	
TITLE:	TREATMENT OF BASAL GANGLIA- RELATED MOVEMENT DISORDERS WITH 2,3-BENZODIAZEPINES	) CONFIRMATION NO.: 350	03

## VIA EFS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

## TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action on the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents, publications and commonly assigned patents and patent applications are believed of interest herein and consideration by the Examiner is respectfully requested.

	Respectfully submitted,	
	/Marina Heusch/	
June 15, 2010		
Date:		
	Marina I. Heusch	
	Patent Agent #47,647	
	Swanson & Bratschun, L.L.C.	
	8210 Southpark Terrace	
	Littleton, CO 80120	
	Telephone: (303) 268-0066	
	Facsimile: (303) 268-0065	